Hospital-wide ELectronic medical record evaluated computerised decision support system to improve outcomes of Patients with staphylococcal bloodstream infection

Conditions

A41.0 A41.1

Palm J, Alaid S, Ammon D, Brandes J, Dürschmid A, Fischer C, Fortmann J, Friebel K, Geihs S, Hartig AK, He D, Heidel AJ, Hetfeld P, Ihle R, Kahle S, Koi V, Konik M, Kretzschmann F, Kruse H, Lippmann N, Lübbert C, Marx G, Mikolajczyk R, Mlocek A, Moritz S, Müller C, Müller S, Pérez Garriga A, Phan-Vogtmann LA, Pietzner D, Pletz MW, Popp M, Rebenstorff M, Renz J, Rißner F, Röhrig R, Saleh K, Schönherr SG, Spreckelsen C, Stempel A, Stolz A, Thomas E, Thon S, Tiller D, Uschmann S, Wendt S, Wendt T, Winnekens P, Witzke O, Hagel S, Scherag A.

2025-03-281 citations

10.1038/s41746-025-01569-3

Hospital-wide ELectronic medical record evaluated computerised decision support system to improve outcomes of Patients with staphylococcal bloodstream infection (HELP): study protocol for a multicentre stepped-wedge cluster randomised trial

Stefan Hagel, Julia Gantner, Cord Spreckelsen, Claudia Fischer, Danny Ammon et al. (34 authors)

BMJ Open2020-02-0110 citations

10.1136/bmjopen-2019-033391

Interventions

Group 1: HELP App (CDSS

digital book) Group 2: TAU ("treatment as usual")

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Staphylococcus spp. bacteremia

Exclusion criteria

Exclusion criteria: Patients from psychiatric wards, pediatric wards and obstetric wards. If treated according to KNS arm: death of patient within 72h after collection of first blood culture.

Design outcomes

Primary

Measure	Time frame
Coprimary endpoints (confirmatory test in the hierarchical order given here): - mortality and relapse rate due to S. aureus within 90 days in the SAB arm (non-inferiority test) and - the cumulative consumption of vancomycin in the CNS arm (superiority test)	—

Secondary

Measure	Time frame
- acute renal failure (KDIGO clinical practice guideline for acute kidney injury) - cumulative consumption of vancomycin, linezolid, teicoplanin, daptomycin, rifampicin, fosfomycin, flucloxacillin, cefazolin - incoming blood culture sets per institution and year - estimation of treatment costs based on ID consultation times and frequencies (only for complicated SAB) as well as technical and process-oriented endpoints from questionnaires (user survey)	—

Measure

Time frame

- acute renal failure (KDIGO clinical practice guideline for acute kidney injury) - cumulative consumption of vancomycin, linezolid, teicoplanin, daptomycin, rifampicin, fosfomycin, flucloxacillin, cefazolin - incoming blood culture sets per institution and year - estimation of treatment costs based on ID consultation times and frequencies (only for complicated SAB) as well as technical and process-oriented endpoints from questionnaires (user survey)

—

Countries

Germany

Contacts

Public ContactAndré Scherag

Institut für Medizinische Statistik, Informatik und Datenwissenschaften (IMSID), Universitätsklinikum Jena

andre.scherag@med.uni-jena.de+49-(0)-3641-9-396954

Outcome results

None listed